Belgian regulator amends guidelines on labelling and packaging of human medicines

Tine Carmeliet

On 1 March 2018, the Federal Agency for Medicines and Health Products (FAMHP) published amended guidelines on the labelling of medicines within the context of new marketing authorisations, renewals or variations for medicines for human use.  Pharmaceutical companies should comply with these guidelines, which stipulate specific requirements for the packaging and labelling of medicines.

The guidelines have been amended to meet European guidelines and other national and international agreements. The main changes include amendments to, inter alia:

  • The definition of small packages and mock-ups.
  • The use of trademarks and logos.
  • The labelling of combination packs.
  • Sections 16-19 of the guidelines in accordance with the European Quality Review of Documents template.

A prior version of this post was originally published by the same authors in Practical Law – Life Sciences, March 2018 issue (Thomson Reuters).

Share
Read comments below or add a comment
Comments published on the Life Sciences Hub do not necessarily reflect the views of Allen & Overy or its clients.

Leave a comment

Your email address will not be published. Required fields are marked *